Drugs / DTaP-IPV
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03848065 | Apr 2019 → Jun 2020 | pneumococcal infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 33 trials · 1 met primary | ||||||
| Phase 3 | NCT04618640 | Dec 2019 → Dec 2020 | diphtheria, pertussis, poliomyelitis, tetanus | Boryung Biopharma Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT01346293 | Apr 2011 → May 2013 | diphtheria, measles, pertussis, poliomyelitis +1 | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
| Phase 3 | NCT00255047 | Nov 2005 → Jul 2008 | diphtheria, pertussis, poliomyelitis | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DTaP-IPV | “The study was designed to compare the safety and immunogenicity of DTap-IPV with DAPTACEL® + IPOL® as the 5th dose booster” NCT01346293 ↗ |
| Known as | DTaP5-IPV | “Immunogenicity and safety of stand-alone diphtheria, tetanus toxoid, 5-component acellular pertussis vaccine adsorbed, inactivated poliovirus (IPV) combination vaccine...” PMID 27879555 ↗ Mar 2017 |
| Known as | QUAD | “Pentavalent and quadrivalent combination vaccine formulations from the same manufacturer (DTaP-IPV/Hib [PENTA], DTaP-IPV [QUAD]) were investigated as to whether they were...” PMID 22475857 ↗ Apr 2012 |
| Modality | Vaccine | “Diphtheria, tetanus, and pertussis-inactivated poliovirus (DTaP-IPV) vaccine” PMID 36882898 ↗ Mar 2023 |
| Route | Intramuscular | “0.5 mL, Intramuscular (DTap-IPV); Subcutaneous (M-M-R®II and VARIVAX®)” NCT01346293 ↗ |